Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESCENT: De-escalated Endocrine Therapy in Early Breast Cancer
NCT07153757Phase 3Not yet recruiting
- Sponsor
- Fudan University
- Start
- Sep 2025
- Primary completion
- Sep 2033
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of tamoxifen, toremifene, letrozole, anastrozole, exemestane in breast cancer, sponsored by Fudan University. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
tamoxifentoremifeneletrozoleanastrozoleexemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07153757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07153757.